Brief: Algernon Submits For Ethics Approval In Australia For Study Of Ifenprodil For Covid-19
15/05/2020 13:51
May 15 (Reuters) - Algernon Pharmaceuticals Inc AGN.CD :
* ALGERNON SUBMITS FOR ETHICS APPROVAL IN AUSTRALIA FOR
MULTINATIONAL PHASE 2B/3 HUMAN STUDY OF IFENPRODIL FOR COVID-19
* ALGERNON PHARMACEUTICALS INC - ALSO PLANNING TO CONDUCT
MULTINATIONAL PHASE 2B/3 CLINICAL STUDY IN CANADA AND U.S
Source text for Eikon: ID:nGNX2wfD9H
Further company coverage: AGN.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grey Matters Health
See all newsBrief: Grey Matters Announces The Closing Of Its Equity And Convertible Debenture Private Placement Totalling CAD $1.12 Million
Brief: Algernon Announces Additional Increase To Private Placement Financing
Brief: Algernon Health Announces Private Placement
Brief: Algernon Announces Closing Of The Private Placement Financing
Brief: Algernon Announces $1 Mln Private Placement